JPH1143432A - 脳の老化抑制及び治療剤 - Google Patents
脳の老化抑制及び治療剤Info
- Publication number
- JPH1143432A JPH1143432A JP9215618A JP21561897A JPH1143432A JP H1143432 A JPH1143432 A JP H1143432A JP 9215618 A JP9215618 A JP 9215618A JP 21561897 A JP21561897 A JP 21561897A JP H1143432 A JPH1143432 A JP H1143432A
- Authority
- JP
- Japan
- Prior art keywords
- group
- brain
- compound
- medicine
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000032683 aging Effects 0.000 title claims abstract description 27
- 210000004556 brain Anatomy 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title abstract description 18
- 229940079593 drug Drugs 0.000 title description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 150000002291 germanium compounds Chemical class 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 102000016943 Muramidase Human genes 0.000 claims description 3
- 108010014251 Muramidase Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 235000010335 lysozyme Nutrition 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- -1 organogermanium compound Chemical class 0.000 abstract description 10
- 239000000243 solution Substances 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 230000000699 topical effect Effects 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 208000013677 cerebrovascular dementia Diseases 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000082 organogermanium group Chemical group 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZJUHNMADISSFJZ-UHFFFAOYSA-N 2-trichlorogermylpropanoic acid Chemical compound OC(=O)C(C)[Ge](Cl)(Cl)Cl ZJUHNMADISSFJZ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001490 effect on brain Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- SFRGJTLLCUCVMH-UHFFFAOYSA-N germanium;propanoic acid Chemical compound [Ge].CCC(O)=O SFRGJTLLCUCVMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9215618A JPH1143432A (ja) | 1997-07-25 | 1997-07-25 | 脳の老化抑制及び治療剤 |
| PCT/JP1998/003287 WO1999004786A1 (fr) | 1997-07-25 | 1998-07-23 | Nhibiteur et agent therapeutique contre le vieillissement cerebral |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9215618A JPH1143432A (ja) | 1997-07-25 | 1997-07-25 | 脳の老化抑制及び治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1143432A true JPH1143432A (ja) | 1999-02-16 |
Family
ID=16675396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9215618A Pending JPH1143432A (ja) | 1997-07-25 | 1997-07-25 | 脳の老化抑制及び治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH1143432A (fr) |
| WO (1) | WO1999004786A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008004340A1 (fr) | 2006-07-05 | 2008-01-10 | Kao Corporation | Inhibiteur de la sénescence |
| JP2021014418A (ja) * | 2019-07-11 | 2021-02-12 | 学校法人近畿大学 | 有機ゲルマニウム化合物を有効成分として含むチオール基含有化合物の捕捉剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05255130A (ja) * | 1992-03-16 | 1993-10-05 | Asai Gerumaniumu Kenkyusho:Kk | メイラード反応抑制改善剤 |
| GB2288732B (en) * | 1994-04-13 | 1998-04-29 | Quadrant Holdings Cambridge | Pharmaceutical compositions |
-
1997
- 1997-07-25 JP JP9215618A patent/JPH1143432A/ja active Pending
-
1998
- 1998-07-23 WO PCT/JP1998/003287 patent/WO1999004786A1/fr active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008004340A1 (fr) | 2006-07-05 | 2008-01-10 | Kao Corporation | Inhibiteur de la sénescence |
| US8962678B2 (en) | 2006-07-05 | 2015-02-24 | Kao Corporation | Senescence inhibitor |
| JP2021014418A (ja) * | 2019-07-11 | 2021-02-12 | 学校法人近畿大学 | 有機ゲルマニウム化合物を有効成分として含むチオール基含有化合物の捕捉剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999004786A1 (fr) | 1999-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6876047B2 (ja) | ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のための化合物 | |
| JP2021181471A (ja) | ピペリジニルインドール誘導体の新規な使用 | |
| CN114085236A (zh) | 醛结合物和其用途 | |
| WO2020259528A1 (fr) | Procédé de traitement de la fibrose pulmonaire idiopathique | |
| WO2020177587A1 (fr) | Méthode de traitement d'une stéatose hépatique et/ou d'une stéatohépatite | |
| JP2022534420A (ja) | 眼のタンパク質凝集疾患を治療するための薬剤 | |
| KR100609381B1 (ko) | 인지 장애 치료방법 | |
| KR20030016231A (ko) | 티아졸륨 화합물, 및 단백질 노화와 관련된 장애의 치료 | |
| JP2020511450A (ja) | ミトコンドリアの活性酸素種（ｒｏｓ）産生に関連する疾患の治療のためのデスメチルアネトールトリチオン誘導体 | |
| JPH1143432A (ja) | 脳の老化抑制及び治療剤 | |
| WO2008057599A2 (fr) | Procédés de traitement de troubles associés à l'abeta et compositions | |
| CA2166017A1 (fr) | Composition pharmaceutique pour la dermatite | |
| US20120010264A1 (en) | Novel medicament for treating cognitive impairment | |
| US11643428B2 (en) | Therapeutic drug for neurodegenerative disease and application thereof | |
| KR20110131942A (ko) | 데커시놀 유도체를 포함하는 약학적 조성물 | |
| JP2003267874A (ja) | 神経変性疾患の治療薬 | |
| KR101712184B1 (ko) | Nrf2 활성화 효능의 세스퀴터핀 화합물 및 이를 유효성분으로 포함하는 약학조성물 | |
| CN113072562B (zh) | 一种GSK-3β抑制剂及其制备方法与应用 | |
| RU2697580C1 (ru) | Новый цинковый комплекс, его получение и применение для терапии заболеваний человека и животных | |
| JP4490536B2 (ja) | 脳血管障害に基づく疾患の予防又は治療薬 | |
| WO2015186144A2 (fr) | Procédé d'inhibition de la bêta-sécrétase au moyen de bis-o-déméthylcurcumine pour la prévention, la prise en charge et le traitement de maladies neurodégénératives | |
| JP2023514236A (ja) | ピラジン化合物およびその調製方法と使用 | |
| JP5820127B2 (ja) | アミロイド線維の形成を伴う神経変性疾患の予防・改善薬 | |
| JP2013509386A (ja) | タウおよびβ−アミロイドが関連する神経変性病の処置および／または治療のためのガンビエロールの利用 | |
| JP2001233835A (ja) | カルノジン酸誘導体およびそれを用いた神経成長因子合成促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080418 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080527 |